Stock Comparison

FOLD vs PFE

Amicus Therapeutics Inc vs Pfizer Inc

The Verdict

PFE takes this one.

FOLD

Amicus Therapeutics Inc

0.1

out of 10

Distressed

Winner

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Head-to-Head

$4.5B

Market Cap

$146.4B

N/A

P/E Ratio

19.5

-4.3%

Profit Margin

11.8%

-12.0%

Return on Equity

8.4%

1.4

Debt-to-Equity

0.7

Not Applicable

Overall Risk

Moderate

0.1

DVR Score

4.0

The Deep Dive

FOLD0.1/10

Amicus Therapeutics (FOLD) was acquired by BioMarin Pharmaceutical for $14.50 cash per share on April 27, 2026, leading to its delisting from Nasdaq on April 28, 2026. This fundamental change means FOLD no longer exists as an independent publicly traded entity. Consequently, it offers no future investment potential, let alone '10x growth potential,' for new or existing investors, as shares are no ...

Full FOLD Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.